Transforming growth factor-β plasma dynamics and post-irradiation lung injury in lung cancer patients

Radiotherapy and Oncology

Volumn 71, Issue 2, 2004, Pages 183-189

  Novakova Jiresova, Alena ^a   Van Gameren, Mieke M ^a   Coppes, Rob P ^a   Kampinga, Harm H ^a   Groen, Harry J M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Endocrine effects of TGF ; Lung cancer; Post irradiation lung injury; Radiation pneumonitis

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ACCURACY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOASSAY; LUNG INJURY; LUNG NON SMALL CELL CANCER; MALE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROTEIN BLOOD LEVEL; RADIATION INJURY; RADIATION PNEUMONIA; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RADIATION PNEUMONITIS; RADIOTHERAPY DOSAGE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 1942446138     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2004.01.019     Document Type: Article

References (42)

1. Abe M., Harpel J.G., Metz C.N., Nunes I., Loskutoff D.J., Rifkin D.B. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem. 216:1994;276-284.
2. Anscher M.S., Crocker I.R., Jirtle R.L. Transforming growth factor-β1 expression in irradiated liver. Radiat Res. 122:1990;77-85.
3. Anscher M.S., Kong F.-M., Andrews K., et al. Plasma transforming growth factor β1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 41:1998;1029-1035.
4. Anscher M.S., Kong F.-M., Jirtle R.L. The relevance of transforming growth factor β1 in pulmonary injury after radiation therapy. Lung Cancer. 19:1998;109-120.
5. Anscher M.S., Kong F.-M., Marks L.B., Bentel G.C., Jirtle R.L. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys. 37:1997;253-258.
6. Anscher M.S., Kong F.-M., Murase T., Jirtle R.L. Short communication: normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGFβ Br J Radiol. 68:1995;331-333.
7. Anscher M.S., Marks L.B., Shafman T.D., et al. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol. 19:2001;3758-3765.
8. Anscher M.S., Marks L.B., Shafman T.D., et al. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 56:2003;988-995.
9. Anscher M.S., Murase T., Prescott D.M., et al. Changes in plasma TGFβ levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys. 30:1994;671-676.
10. Barcellos-Hoff M.H., Derynck R., Tsang M.L.-S., Weatherbee J.A. Transforming growth factor-β activation in irradiated murine mammary gland. J Clin Invest. 93:1994;892-899.
11. Barthelemy-Brichant N., David J.L., Bosquee L., et al. Increased TGFbeta1 plasma level in patients with lung cancer: potential mechanisms. Eur J Clin Invest. 32:2002;193-198.
12. Bayat A., Bock O., Mrowietz U., Ollier W.E., Ferguson M.W. Genetic susceptibility to keloid disease and hypertrophic scarring: transforming growth factor beta1 common polymorphisms and plasma levels. Plast Reconstr Surg. 111:2003;535-543.
13. Chen Y., Williams J., Ding I., et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol. 12:2002;26-33.
14. de Caestecker M.P., Piek E., Roberts A.B. Role of transforming growth factor-β signaling in cancer. J Natl Cancer Inst. 92:2000;1388-1402.
15. de Jaeger K., Seppenwoolde Y., Kampinga H.H., Boersma L.J., Belderbos J.S.A., Lebesque J.V. Significance of plasma transforming growth factor-β levels for radiotherapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;. in press.
16. Dickson J., Davidson S.E., Hunter R.D., West C.M. Pretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 48:2000;991-995.
17. Emami B., Perez C.A. Perez C.A., Brady L.W. Principles and practice of radiation oncology. 2nd ed. 1992;829 J. B. Lippincott Company, Philadelphia.
18. Fletcher G.H. Clinical dose-response curves of human malignant epithelial tumours. Br J Radiol. 46:1973;1-12.
19. 30 and transforming growth factor β Int J Radiat Oncol Biol Phys. 50:2001;899-908.
20. Grainger D.J., Mosedale D.E., Metcalfe J.C. TGF-β in blood: a complex problem. Cytokine Growth Factor Rev. 11:2000;133-145.
21. Hernando M.L., Marks L.B., Bentel G.C., et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 51:2001;650-659.
22. Junker U., Knoefel B., Nuske K., et al. Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine. 8:1996;794-798.
23. Kong F.-M., Anscher M.S., Murase T., Abbott B.D., Iglehart J.D., Jirtle R.L. Elevated plasma transforming growth factor-beta1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg. 222:1995;155-162.
24. Kong F., Jirtle R.L., Huang D.H., Clough R.W., Anscher M.S. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer. 86:1999;1712-1719.
25. Kong F.-M., Washington M.K., Jirtle R.L., Anscher M.S. Plasma transforming growth factor-β1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer. 16:1996;47-59.
26. Krasagakis K., Tholke D., Farthmann B., Eberle J., Mansmann U., Orfanos C.E. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer. 77:1998;1492-1494.
27. Li C., Wang J., Wilson P.B., et al. Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer. Int J Cancer. 79:1998;455-459.
28. Li C., Wilson P.B., Levine E., Barber J., Stewart A.L., Kumar S. TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int J Cancer. 84:1999;155-159.
29. Lyons R.M., Gentry L.E., Purchio A.F., Moses H.L. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J Cell Biol. 110:1990;1361-1367.
30. Marks L.B., Fan M., Clough R., et al. Radiation-induced pulmonary injury: symptomatic versus subclinical endpoints. Int J Radiat Biol. 76:2000;469-475.
31. Marks L.B., Munley M.T., Bentel G.C., et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys. 39:1997;563-570.
32. Martel M.K., Ten Haken R.K., Hazuka M.B., et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer. 24:1999;31-37.
33. Martin M., Lefaix J.-L., Delanian S. TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys. 47:2000;277-290.
34. Martin M., Lefaix J.-L., Pinton P., Crechet F., Daburon F. Temporal modulation of TGF-β1 and β-actin gene expression in pig skin and muscular fibrosis after ionizing radiation. Radiat Res. 134:1993;63-70.
35. Narai S., Watanabe M., Hasegawa H., et al. Significance of transforming growth factor beta1 as a new tumor marker for colorectal cancer. Int J Cancer. 97:2002;508-511.
36. Rubin P., Johnston C.J., Williams J.P., McDonald S., Finkelstein J.N. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 33:1995;99-109.
37. Saunders M., Dische S., Barrett A., Harvey A., Griffiths G., Parmar M., (on behalf of the CHART Steering committee). Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol. 52:1999;137-148.
38. van Waarde M.A.W.H., van Assen A.J., Kampinga H.H., Konings A.W.T., Vujaskovic Z. Quantification of transforming growth factor-β in biological material using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem. 247:1997;45-51.
39. Vujaskovic Z., Groen H.J.M. TGF-β, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol. 76:2000;511-516.
40. Vujaskovic Z., Marks L.B., Anscher M.S. The physical parameters and molecular events associated with radiation-induced lung toxicity. Semin Radiat Oncol. 10:2000;296-307.
41. Wakefield L.M., Letterio J.J., Chen T., et al. Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res. 1:1995;129-136.
42. Wakefield L.M., Winokur T.S., Hollands R.S., Christopherson K., Levinson A.D., Sporn M.B. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest. 86:1990;1976-1984.